Skip to main content
. 2016 Mar 10;7(17):23322–23334. doi: 10.18632/oncotarget.8019

Figure 3. Drug-β-CN morphology and crystallinity visualization.

Figure 3

Nomarski DIC (left) and polarized light (right) microscopy images (×20 magnification) of: (A) 667 μM, (C) 833 μM pure PTX in PBS vs. (B) 667 μM, (D) 833 μM PTX in 1 mg/ml β-CN (16:1, 20:1 drug:β-CN molar ratio, respectively) and (E) 208 μM, (G) 333 μM pure TQD in PBS vs. (F) 208 μM, (H) 333 μM TQD in 1 mg/ml β-CN (5:1, 8:1 drug:β-CN molar ratio, respectively). Scale bar: 100 μm.